 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

C4 Therapeutics, Inc. (NASDAQ:CCCC  Get Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 5,290,000 shares, a growth of...

C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Significant Increase in Short Interest

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC  Get Free Report) dropped 3.9% during mid-day trading on Wednesday . The company traded as low as $8.35 and last traded at $8.35. Approximately...

C4 Therapeutics (NASDAQ:CCCC) Trading Down 3.9%

C4 Therapeutics, Inc. (NASDAQ:CCCC  Get Free Report) shares dropped 6.8% during trading on Thursday . The company traded as low as $9.92 and last traded at $10.00. Approximately 560,028 shares...

C4 Therapeutics (NASDAQ:CCCC)  Shares Down 6.8%

This is a signal that CCCC's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

C4 Therapeutics (CCCC, $10.62) RSI Indicator left the overbought zone on March 11, 2024

C4 Therapeutics (CCCC, $11) RSI Indicator left the overbought zone on March 08, 2024

C4 Therapeutics (CCCC, $10.58) RSI Indicator left the overbought zone on March 07, 2024

CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain MetastasisWATERTOWN...

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC  Degraders at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics, Inc. (NASDAQ:CCCC  Get Free Report) was the recipient of a significant drop in short interest during the month of February. As of February 15th, there was short interest...

C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update

Algert Global LLC trimmed its stake in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC  Free Report) by 12.4% in the third quarter, according to the company in its most recent filing with the...

Algert Global LLC Has $96,000 Stock Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

C4 Therapeutics announces research collaboration with Merck KGaA

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.

Volume (M)	120.00
52-Wk High	$11.88
52-Wk Low	$1.06

CCCC C4 Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals